共 279 条
[1]
Du Pan SM(2009)Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis Arthritis Rheum 61 560-568
[2]
Dehler S(2016)Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry Arthritis Care Res (Hoboken) 68 432-439
[3]
Ciurea A(2010)Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry Arthritis Rheum 62 22-32
[4]
Ziswiler HR(2015)Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab Ann Rheum Dis 74 354-360
[5]
Gabay C(2016)Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases Rheumatology (Oxford) 55 523-534
[6]
Finckh A(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-977
[7]
Favalli EG(2015)Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges Nat Rev Rheumatol 11 276-289
[8]
Pregnolato F(2012)Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients Ann Rheum Dis 71 997-999
[9]
Biggioggero M(2014)Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies Rheumatology (Oxford) 53 1664-1668
[10]
Becciolini A(2004)Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues Ann Rheum Dis 63 ii13-ii17